Navigation Links
NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
Date:4/28/2011

y result from the expected patent issuance.  Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the development of NGX-1998 and obtaining marketing approval for NGX-1998, difficulties or delays in the commercialization of Qutenza®, physician or patient reluctance to use Qutenza® or other products developed by NeurogesX despite the Company's commercialization efforts and strategies, difficulties or delays in the further development of Qutenza® for additional indications, and difficulties in maintaining patents and patent protection for NeurogesX products and product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

Executive Vice President, COO

and CFO

(650) 358-3310




The Ruth Group

Stephanie Carrington (investors)

(646) 536-7017

scarrington@theruthgroup.com


Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com





'/>"/>
SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , Indien, August 1, 2014 ... BioQuiddity Inc. gaben heute bekannt, vor kurzem ... Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen Eingriffen eine ... Gebiet der Europäischen Union und weiterer europäischer ... versehene und mit Ropivacain gefüllte OneDose ReadyfusOR ...
(Date:7/31/2014)... 31, 2014  According to data released today by ... average monthly Medicare Part D premium is expected to ... was originally projected, the Pharmaceutical Care Management Association (PCMA) ... to be a bright spot in American health care. ... region and using cutting edge, cost-saving tools like pharmacy ...
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... STXS ) announced today the appointment of ... (EMEA) to lead the Company,s EMEA operations and sales ... utilization of its Niobe® Remote Magnetic Navigation System and ... P. Kaminski, President and CEO of Stereotaxis. ...
... Biosciences, Inc. (Nasdaq: NBIX ) today announced its financial ... For the third quarter of 2010, the Company reported net income ... loss of $8.2 million, or $0.21 per share, for the same ... the Company reported a net loss of $10.5 million, or $0.20 ...
Cached Medicine Technology:Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations 2Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations 3Neurocrine Biosciences Reports Third Quarter 2010 Results 2Neurocrine Biosciences Reports Third Quarter 2010 Results 3Neurocrine Biosciences Reports Third Quarter 2010 Results 4Neurocrine Biosciences Reports Third Quarter 2010 Results 5Neurocrine Biosciences Reports Third Quarter 2010 Results 6Neurocrine Biosciences Reports Third Quarter 2010 Results 7Neurocrine Biosciences Reports Third Quarter 2010 Results 8
(Date:7/31/2014)... 2014 The 2013 edition of ... chemical listings, appellate decisions, litigation and settlement trends, ... compliance with California's Proposition 65. , The Handbook ... regulations, history and trends impacting California's Proposition 65. ... of the series which adds approximately 200 pages ...
(Date:7/31/2014)... On October 10, at the Palmer ... Applied Research Foundation, in collaboration with the University ... mesothelioma conference geared to patients and ... to mesothelioma and presented by local and regional ... include imaging, genetics, first-line therapies, surgery, chemotherapy, radiation ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:7/31/2014)... Nashville, TN (PRWEB) July 31, 2014 ... TN was one of the first surgeons in the United ... the iStent, the smallest medical device ever approved ... the first surgeons to recognize the benefits of using a ... patients with glaucoma. Dr. Shofner and his colleagues now recognize ...
(Date:7/31/2014)... 2014 The vineyards are lush, and the ... And, to celebrate, folks are gearing up for the annual ... and 7, 2014 along the Leelanau Peninsula Wine Trail ... or run through the vineyards start-ing at 9:00 a.m. on ... unique course between rows of grapevines offers an experience like ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2
... , TUESDAY, Feb. 21 (HealthDay News) -- Insulin production may ... according to a new study. The findings add to ... the onset of the disease is longer than previously believed, ... thought that beta cell function completely ceased in patients with ...
... recession was the longest and most severe since World War ... at the slowest rate in over 50 years, suggesting that ... that these cut backs were not limited to Americans who ... at the University of North Carolina at Chapel Hill School ...
... , New Rochelle, NY, February 21, 2012Faith-based advocacy has ... obesity, but evidence is needed to support this assertion ... policy can contribute to promoting permanent lifestyle changes. This ... journal Childhood Obesity celebrating the second anniversary ...
... News) -- Researchers who traced the evolution of a ... livestock to humans say their findings highlight the dangers ... The international team of scientists studied methicillin-resistant Staphylococcus ... livestock-associated MRSA, which most often infects people with direct ...
... By reformulating the common cancer drug imatinib (Gleevec), researchers ... step toward improving the effectiveness of chronic pain management ... Texas MD Anderson Cancer Center. Narcotics such as ... time, tolerance to the pain-relieving effects of these drugs ...
... rescues malignant cells from destruction by extending the protective caps ... triggers resistance pathways that allow cancer to survive and spread, ... . "Telomerase is overexpressed in many advanced cancers, but ... understand what it does and how it does it," said ...
Cached Medicine News:Health News:Type 1 Diabetes May Develop More Slowly Than Thought 2Health News:Recession and high co-pays tied to fewer colonoscopy screenings among people with health insurance 2Health News:Childhood obesity -- can faith-based organizations make a difference? 2Health News:Pig-to-Human 'Superbug' May Be Due to Animal Antibiotics 2Health News:Reformulated imatinib eliminates morphine tolerance in lab studies 2Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 2Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 3Health News:Blocking telomerase kills cancer cells but provokes resistance, progression 4
Inquire...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
... Aerosol barrier tips eliminate false signals ... designed and tested, Promega Barrier Tips ... with amplified nucleic acids (PCR(a)), radioactive ... forensic and serological specimens. , ,Promega ...
... a safe alternative to using positive displacement ... such as PCR(a), pipetting radioactive materials and ... excellent for tissue culture, gel loading, serological ... aerosol contaminants and liquids from reaching the ...
Medicine Products: